^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Triple Negative Breast Cancer
    Drug:emiltatug ledadotin (XMT-1660) (Tubulin inhibitor, B7-H4-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Mersana Therapeutics Press Release
    Title:

    Mersana Therapeutics Announces FDA Fast Track Designation Granted to XMT-1660 for the Treatment of Triple-Negative Breast Cancer

    Published date:
    09/12/2022
    Excerpt:
    Mersana Therapeutics...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC).